Microba Life Sciences Limited (ASX:MAP)
Australia · Delayed Price · Currency is AUD 0.0750
-0.0020 (-2.60%)
May 18, 2026, 3:02 PM AEST
Microba Life Sciences Company Description
Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States.
It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; Databank, for discovery of therapeutic leads, consumer health innovations, and diagnostic biomarkers; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel disease, cancer immunotherapy, and autoimmune diseases.
The company was incorporated in 2017 and is based in Brisbane, Australia.
Microba Life Sciences Limited
| Country | Australia |
| Founded | 2017 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| CEO | Luke Reid |
Contact Details
Address: 324 Queen Street Brisbane, QLD QLD Australia | |
| Phone | 61 13 0097 4621 |
Stock Details
| Ticker Symbol | MAP |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000209868 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Dr. Luke Reid | Chief Executive Officer |
| Prof. Gene Tyson | Co-Founder and Non-Executive Director |
| James Heath | Chief Financial Officer and Company Secretary |
| Prof. Philip Hugenholtz | Co-Founder and Chair of Scientific Advisory Board |
| Dr. David Wood | Chief Technology Officer |
| Prof. Lutz Krause | Chief Scientific Officer |
| Dr. Nicola Angel | Head of Laboratory Operations and Laboratory Director |
| Keith Byrne | Head of Test Operations |
| Eric Davies | Chief Revenue Officer |
| Alaster Stockwell-Jones | Managing Director of UK |